HOUSTON--(BUSINESS WIRE)--Tvardi Therapeutics (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced the appointment of Sujal Shah, Chief Executive Officer of CymaBay Therapeutics, to its Board of Directors.
Mr. Shah brings two decades of experience as an operator and advisor in the biotechnology sector to the Tvardi Board. Since 2017, he has been President and Chief Executive Officer at CymaBay Therapeutics, a clinical-stage biopharmaceutical company developing innovative therapies for patients with liver and other chronic diseases. Previously, he served as Chief Financial Officer of CymaBay, taking the company public in 2014. Prior to CymaBay, Mr. Shah was a healthcare investment banker for Citigroup as well as Credit Suisse, where he was responsible for managing client relationships and executing strategic and financing related transactions for clients focused on life sciences.
“Tvardi is thrilled to have Sujal join our board,” stated Ronald DePinho, M.D., Tvardi’s Chairman of the Board of Directors. “His experience in navigating financial markets and investors as well as operating and scaling a biotech company are incredibly relevant as Tvardi grows and becomes successful.”
Mr. Shah added, “Tvardi is at an exciting juncture in its brief history as it advances its STAT3 platform across multiple clinical indications including cancer and fibrosis. I look forward to working alongside the Board and management during this growth phase of the company.”
Mr. Shah also serves on the Executive Advisory Board of the Chemistry of Life Processes Institute at Northwestern University. He received an M.B.A. from Carnegie Mellon University Tepper School of Business and M.S. and B.S. degrees in Biomedical Engineering from Northwestern University.
About Tvardi Therapeutics, Inc.
Tvardi is a privately held, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3. STAT3 is a key regulatory protein positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells as well as to the pathogenesis of many inflammatory and fibrotic diseases. Early clinical studies have shown that the company’s lead asset in cancer, TTI-101, is well tolerated and has clinical activity across a broad range of tumors including multiple durable responses. To learn more, visit www.tvardi.com.